EpiPen

Janney: Cannabis, Naloxone, Adrenaline The Perfect Mix For Insys

Analyst: Insys To Benefit As FDA Pushes Naloxone Access

Teva Wins FDA Approval For Generic Epinephrine

Analyst: Insys To Benefit As FDA Pushes Naloxone Access

Teva Wins FDA Approval For Generic Epinephrine

Mylan's Stock Is No Longer A Buy According To Analysts At Argus

A Peek At Adamas Ahead Of FDA Approval

Mylan's Stock Is No Longer A Buy According To Analysts At Argus

A Peek At Adamas Ahead Of FDA Approval

It's Easy To Be Skeptical Of Mylan, But Don't Ignore This Pending PDUFA Date

What Makes Mylan's Newest EpiPen Lawsuit Different?

EpiPen Recent News

Imprimis Challenges Mallinckrodt's Acthar

How Did A Maligned Mylan Surprise To The Upside With 2017 Outlook?

Short Sellers Bet Against Generic EpiPen

Mylan's EpiPen Dropped From Cigna's Coverage List

How Does Mylan's $300 Choice Compare To Other Generic EpiPens?

Andrew Left Challenges Mallinckrodt, Compares Acthar To The EpiPen

Mylan's Q3 Report Tries, Fails To Shift Focus Away From EpiPen Controversy

The Things You Need To Know Ahead Of Mylan's Q3 Earnings

Mylan Surrenders Some Of Its Gains From EpiPen Settlement

Mylan Analysts Respond Positively Following EpiPen Classification Settlement

After-Hours: 2 Stocks On The Move On Another Slow Friday Afternoon

Epipen's Profits Are Actually A Lot Higher Than Mylan Originally Told Congress

USA Today On EpiPen Saga: Calling It 'Controversial' Is Far From Haphazard

Controversy Pullback Offers Good Entry Point For Mylan

Mylan's CEO Showed 'Very Little Empathy,' Bill George Says

Mylan Investors Should Be Asking Where (And Who) Robert Coury Is

Another Election Year View On Healthcare ETFs

MannKind Is 'Making Progress' On Its Alternative To Mylan's EpiPen, Report Says

Mylan Announces $300 Version Of EpiPen

Pharma Companies Are Spending Millions To Sustain High Drug Prices

Mylan Is Offering An EpiPen Savings Card, But A Lot Of People Will Still Get Screwed

Selling Pressure Continues For Mylan

Mylan 'Took The Sting' Out Of The EpiPen Controversy